Jennifer Gudeman's guest appearances

Jennifer Gudeman

Empowered Patient Podcast

Narcolepsy 360

Mark Allen

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

OwlTail

Dr. Jennifer Gudeman was hired for the newly formed role of Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals. We talk about the clinical development of their lead investigational product FT218 to treat the rare disease narcolepsy. Optimized the drug delivery release of sodium oxybate with their proprietary controlled-release technology allows for a single bedtime dose. While the FDA nearly 20 years ago approved sodium oxybate to treat cataplexy and excessive daytime sleepiness, the drug was an immediate-release medication requiring a middle-of-the-night dose. After a successful Phase 3 clinical trial, Avadel's ongoing open-label study, RESTORE, is providing evidence that points to more restorative sleep across a broad audience. @AvadelPharma $AVDL #narcolepsy #cataplexy #sleepdisorders #sleep #EDS #neurotwitter #rarediseases Avadel.com Download the transcript here

Dr. Jennifer Gudeman was hired for the newly formed role of Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals. We talk about the clinical development of their lead investigational product FT218 to treat the rare disease narcolepsy. Optimized the drug delivery release of sodium oxybate with their proprietary controlled-release technology allows for a single bedtime dose. While the FDA nearly 20 years ago approved sodium oxybate to treat cataplexy and excessive daytime sleepiness, the drug was an immediate-release medication requiring a middle-of-the-night dose. After a successful Phase 3 clinical trial, Avadel's ongoing open-label study, RESTORE, is providing evidence that points to more restorative sleep across a broad audience. @AvadelPharma $AVDL #narcolepsy #cataplexy #sleepdisorders #sleep #EDS #neurotwitter #rarediseases <a href="http://Avadel.com" rel="noopener nofollow" target="_blank">Avadel.com</a> <a href="http://empoweredpatientradio.com/treating-narcolepsy-with-once-nightly-controlled-release-sodium-oxybate-with-dr-jennifer-gudeman-avadel-pharmaceuticals-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Treating Narcolepsy with Once Nightly Controlled-Release Sodium Oxybate with Dr. Jennifer Gudeman Avadel Pharmaceuticals

Dr. Jennifer Gudeman is the Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals. In this episode, Dr. Gudeman and Claire discuss how Avadel Pharmaceuticals is seeking FDA approval for a once-nightly form of sodium oxybate (FT218) for the treatment of EDS and cataplexy in people with narcolepsy.  Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs at Avadel in December 2020. Avadel is a global biopharmaceutical company committed to improving the standard of care for people with narcolepsy. Dr. Gudeman and her team are focused on publications of primary and secondary data from the phase 3 REST-ON trial of investigational once-nightly FT218 and building out the medical affairs programs. They are also leading an ongoing open-label extension clinical study, called Restore, to evaluate the long-term safety and tolerability of investigational once-nightly FT218. Dr. Gudeman has published numerous peer-reviewed papers and provided domestic and international presentations on partnership with industry for drug development. In 2017, Dr. Gudeman received the Healthcare Businesswomen’s “Rising Star” award. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that commercial medications fulfill their clinically proven therapeutic benefits to patients and providers. Prior to joining Avadel, Dr. Gudeman was Vice President, Medical Affairs at AMAG Pharmaceuticals, overseeing a team of medical science liaisons and scientific communications. Dr. Gudeman graduated summa cum laude with a bachelor’s degree in pharmacy and magna cum laude with a doctorate in pharmacy from St. Louis College of Pharmacy in 1999 and 2000, respectively. To find out more information about Avadel’s Restore Study please go here. You can follow Wake Up Narcolepsy at @narcolepsy_360 on Instagram, @wakeupnarcolepsy on Instagram and Facebook and @wakenarcolepsy on Twitter. Let us know your thoughts about this episode by using the hashtag #narcolepsy360 and please rate and review us on Apple Podcasts.

Dr. Jennifer Gudeman is the Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals. In this episode, Dr. Gudeman and Claire discuss how Avadel Pharmaceuticals is seeking FDA approval for a once-nightly form of sodium oxybate (FT218) for the treatment of EDS and cataplexy in people with narcolepsy.  Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs at Avadel in December 2020. Avadel is a global biopharmaceutical company committed to improving the standard of care for people with narcolepsy. Dr. Gudeman and her team are focused on publications of primary and secondary data from the phase 3 REST-ON trial of investigational once-nightly FT218 and building out the medical affairs programs. They are also leading an ongoing open-label extension clinical study, called Restore, to evaluate the long-term safety and tolerability of investigational once-nightly FT218. Dr. Gudeman has published numerous peer-reviewed papers and provided domestic and international presentations on partnership with industry for drug development. In 2017, Dr. Gudeman received the Healthcare Businesswomen’s “Rising Star” award. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that commercial medications fulfill their clinically proven therapeutic benefits to patients and providers. Prior to joining Avadel, Dr. Gudeman was Vice President, Medical Affairs at AMAG Pharmaceuticals, overseeing a team of medical science liaisons and scientific communications. Dr. Gudeman graduated summa cum laude with a bachelor’s degree in pharmacy and magna cum laude with a doctorate in pharmacy from St. Louis College of Pharmacy in 1999 and 2000, respectively. To find out more information about Avadel’s Restore Study please go <a href="https://www.wakeupnarcolepsy.org/research/clinical-trials/" rel="nofollow" target="_blank">here</a>. You can follow Wake Up Narcolepsy at <a href="https://www.instagram.com/narcolepsy_360/" rel="noopener nofollow" target="_blank">@narcolepsy_360</a> on Instagram, <a href="https://www.instagram.com/wakeupnarcolepsy/" rel="noopener nofollow" target="_blank">@wakeupnarcolepsy</a> on Instagram and Facebook and <a href="https://twitter.com/wakenarcolepsy" rel="noopener nofollow" target="_blank">@wakenarcolepsy</a> on Twitter. Let us know your thoughts about this episode by using the hashtag #narcolepsy360 and please rate and review us on Apple Podcasts.

Narcolepsy 360: Dr. Jennifer Gudeman